{
    "nct_id": "NCT05246670",
    "official_title": "Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial",
    "inclusion_criteria": "* Age >= 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2\n\n  * NOTE: Patients with a history of metastatic cancer or an ECOG performance status of 2 must have laboratory (lab) work completed =< 28 days prior to registration\n* Pain, numbness, tingling or other symptoms of CIPN of >= 3 months (90 days) duration for which the patient is seeking an intervention\n* Neurotoxic chemotherapy must have been completed >= 3 months (90 days) prior to registration and there must be no further planned neurotoxic -chemotherapy for > 2 months after registration Note: The study is limited to those with taxane- and/or platinum-based neuropathy\n* Patient must note tingling, numbness or pain symptoms of at least a four out of ten =< 7 days prior to registration.\n\n  * Note: On a 0-10 scale where zero was 'no problem' and ten being 'as bad a problem that could be imagined': how much of a problem has numbness, tingling, and/or pain in your fingers and/or toes been in the past week?\n* Patient must be able to speak, read and comprehend English\n* For women of childbearing potential only, a negative urine or serum pregnancy test done =< 14 days prior to registration is required\n\n  * A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\n\n    * NOTE: If the urine test cannot be confirmed as negative, a serum pregnancy test will be required\n* Life expectancy >= 6 months\n* Platelet count > 100,000/mm^3\n\n  * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration\n* Absolute neutrophil count (ANC) >= 1,000/mm^3\n\n  * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration\n* Hemoglobin > 11 g/dL\n\n  * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration\n* Serum transaminase (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) =< 1.2 x upper limit of normal (ULN)\n\n  * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have these labs completed =< 28 days prior to registration\n* Alkaline phosphatase =< 1.2 x ULN\n\n  * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration\n* Serum creatinine =< 1.2 x ULN\n\n  * NOTE: Patients with a history of metastatic cancer or an ECOG performance status of 2 must have this lab completed =< 28 days prior to registration\n* Able to swallow oral medication\n* Provide written informed consent =< 28 days prior to registration\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Currently receiving neurotoxic chemotherapy for a second cancer or recurrence of the primary cancer\n* Impaired decision-making capacity (such as with a diagnosis of dementia or memory loss)\n* Evidence of residual cancer, per routine clinical practice-based parameters\n* Comorbid conditions:\n\n  * Previous diagnosis of diabetic or another non chemotherapy induced peripheral neuropathy\n  * Previous history of peripheral neuropathy prior to receiving neurotoxic chemotherapy\n  * Neuropathy from human immunodeficiency virus (HIV) infection. Note: Patients with HIV infections are eligible as long as they do not have a neuropathy from their viral illness\n* Concurrent use of a cannabis product (tetrahydrocannabinol [THC] and/or cannabidiol [CBD]). Patients should have discontinued these products >= 4 weeks prior to registration\n* Current or previous use of PEA\n* Currently receiving or planning to start any of the following agents: opioids, duloxetine, gabapentin or pregabalin. Patients are eligible if they discontinue these medications >= 1 week prior to registration\n* Any of the following because the study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential who are unwilling to employ adequate contraception",
    "miscellaneous_criteria": ""
}